GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » Gross-Profit-to-Asset %

Icure Pharmaceutical (XKRX:175250) Gross-Profit-to-Asset % : 10.70% (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Icure Pharmaceutical's annualized Gross Profit for the quarter that ended in Mar. 2025 was ₩13,723 Mil. Icure Pharmaceutical's average Total Assets over the quarter that ended in Mar. 2025 was ₩128,308 Mil. Therefore, Icure Pharmaceutical's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 10.70%.


Icure Pharmaceutical Gross-Profit-to-Asset % Historical Data

The historical data trend for Icure Pharmaceutical's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icure Pharmaceutical Gross-Profit-to-Asset % Chart

Icure Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.89 -2.27 -2.54 0.67 5.09

Icure Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.55 4.87 6.12 3.19 10.70

Competitive Comparison of Icure Pharmaceutical's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Icure Pharmaceutical's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Icure Pharmaceutical's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Icure Pharmaceutical's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Icure Pharmaceutical's Gross-Profit-to-Asset % falls into.


;
;

Icure Pharmaceutical Gross-Profit-to-Asset % Calculation

Icure Pharmaceutical's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=7607.2/( (166137.497+132883.281)/ 2 )
=7607.2/149510.389
=5.09 %

Icure Pharmaceutical's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=13722.848/( (132883.281+123733.072)/ 2 )
=13722.848/128308.1765
=10.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Icure Pharmaceutical Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Icure Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR
Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical Headlines

No Headlines